HORIZON THERAPEUTICS

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2020–2023

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
FORBES-TATE	—	17

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	16
SENATE	16

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	17
Medicare/Medicaid	Medicare/Medicaid	16
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	2
Budget/Appropriations	Budget/Appropriations	2

Bills Explicitly Cited (6)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2023 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to pharmaceutical drugs; Issues related to drug pricing; Issues related to drug pricing in H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Medicare Part D; Issues related to policies affecting biopharma products coverage and access in Medicare and Medicaid.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2023 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to pharmaceutical drugs; Issues related to drug pricing; Issues related to drug pricing in H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Medicare Part D; Issues related to policies affecting biopharma products coverage and access in Medicare and Medicaid.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · fourth_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to pharmaceutical drugs; Issues related to drug pricing; Issues related to drug pricing in H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Medicare Part D; Issues related to policies affecting biopharma products coverage and access in Medicare and Medicaid.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 5376

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2022 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to pharmaceutical drugs; Issues related to drug pricing; Issues related to drug pricing in H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Medicare Part D; Issues related to policies affecting biopharma products coverage and access in Medicare and Medicaid.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 5376

Show 2 more cited filings

H.R. 925116th Congress

The Heroes Act

2020 · fourth_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to H.R. 925 - The Heroes Act.

Client expense: — · Firm income: $30,000

Matched citations: H.R. 925

H.R. 925116th Congress

The Heroes Act

2020 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to H.R. 925 - The Heroes Act.

Client expense: — · Firm income: $30,000

Matched citations: H.R. 925

Source: Senate LDA

HORIZON THERAPEUTICS — Lobbying Disclosure | Poliscope